Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4):an observational nationwide study applying linkage between DANBIO and national registries

Autor: Stylianos Georgiadis, Kamilla Danebod, Jolanta Grydehøj, Merete Lund Hetland, Johnny Lillelund Raun, Stavros Chrysidis, Salome Kristensen, Charlotte Wiell, Bente Glintborg, Natalia Manilo, Anders Villumsen, Hanne Merete Lindegaard, Dorte Vendelbo Jensen, Frank Mehnert, Mette Nørgaard, Anne Gitte Loft, Niels Steen Krogh, Grith Eng, Oliver Hendricks, Asta Linauskas, B. L. Andersen

Publikováno v: Glintborg, B, Georgiadis, S, Loft, A G, Linauskas, A, Lindegaard, H, Hendricks, O, Jensen, D V, Andersen, B L, Danebod, K, Villumsen, A, Eng, G, Wiell, C, Manilo, N, Kristensen, S, Raun, J, Grydehøj, J, Chrysidis, S, Nørgaard, M, Mehnert, F, Krogh, N S & Hetland, M L 2020, ' Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4) : an observational nationwide study applying linkage between DANBIO and national registries ', Annals of the Rheumatic Diseases, vol. 79, no. 6, pp. 846-848 . https://doi.org/10.1136/annrheumdis-2019-216702
Glintborg, B, Georgiadis, S, Loft, A G R, Linauskas, A, Lindegaard, H, Hendricks, O, Jensen, D V, Lange Andersen, B, Danebod, K, Villumsen, A, Eng, G, Wiell, C, Manilo, N, Kristensen, S, Raun, J L, Grydehøj, J, Chrysidis, S, Nørgaard, M, Mehnert, F, Krogh, N S & Lund Hetland, M 2020, ' Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries ', Annals of the Rheumatic Diseases, bind 79, nr. 6 . https://doi.org/10.1136/annrheumdis-2019-216702
Glintborg, B, Georgiadis, S, Loft, A G, Linauskas, A, Lindegaard, H, Hendricks, O, Jensen, D V, Andersen, B L, Danebod, K, Villumsen, A, Eng, G, Wiell, C, Manilo, N, Kristensen, S, Raun, J, Grydehøj, J, Chrysidis, S, Nørgaard, M, Mehnert, F, Krogh, N S & Hetland, M L 2020, ' Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4) : An observational nationwide study applying linkage between DANBIO and national registries ', Annals of the rheumatic diseases, vol. 79, no. 6, pp. 846-848 . https://doi.org/10.1136/annrheumdis-2019-216702

Recent international guidelines recommend the use of biosimilar biological drugs on similar terms as their corresponding originators, including switching from a bio-originator to the biosimilar.1 However, the comparative safety of biosimilars in pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b67904a17aae6d2a100c9d8e44060c0e
https://vbn.aau.dk/da/publications/1af94544-8bca-444e-aa8a-980b51288dff

Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study

Autor: Klaus Bendtzen, M Stoltenberg, Emina Omerovic, Grith Eng, Hanne Merete Lindegaard, Elmo K Jensen, Viktoria Fana, Pil Højgaard, Henning Bliddal, Marcin Szkudlarek, Pierre Bouchelouche

Publikováno v: Eng, G P, Bendtzen, K, Bliddal, H, Stoltenberg, M, Szkudlarek, M, Fana, V, Lindegaard, H M, Omerovic, E, Højgaard, P, Jensen, E K & Bouchelouche, P N 2015, ' Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission : a cross-sectional study ', Arthritis Today, vol. 2015, 784825 . https://doi.org/10.1155/2015/784825
Arthritis
Arthritis, Vol 2015 (2015)

Objective. To investigate if antibodies towards biological TNF-α inhibitors (anti-TNFi Abs) are present in patients with rheumatoid arthritis (RA) in clinical remission and to relate any anti-TNFi Abs to circulating level of TNF-α inhibitor (TNFi).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71ddd21d618b30460ac49ea07953e270
https://doi.org/10.1155/2015/784825

Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study

Autor: M Stoltenberg, Klaus Bendtzen, Else Marie Bartels, Grith Eng, Pierre Bouchelouche, Henning Bliddal

Publikováno v: PLoS ONE, Vol 11, Iss 9, p e0162316 (2016)
PLoS ONE

Objectives With the present study we wanted to explore the impact of treatment with a tumor necrosis factor-α -inhibitor (TNFi) on levels of soluble biomarkers in rheumatoid arthritis (RA) patients and to identify predictors of impaired drug levels

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5a21051d56cafb57a3929ffe8b32a39
https://doi.org/10.1371/journal.pone.0162316

AB0663 Efficacy and Safety of Adalimumab in Patients with Axial Spondyloarthritis - An Investigator-Initiated Randomized Placebo-Controlled Trial: Table 1

Autor: Ole Rintek Madsen, Grith Eng, Mette Østergaard, Inge Juul Sørensen, Simon Krabbe, Jakob M Møller, Susanne Juhl Pedersen, Bente Jensen, Lone Balding, Karsten Asmussen

Publikováno v: Annals of the Rheumatic Diseases. 75:1131.3-1132

Background This study investigates the effect of adalimumab (ADA) in patients with axial spondyloarthritis (axSpA). Objectives In an investigator-initiated randomized, placebo-controlled, double-blinded trial (NCT01029847) the efficacy of adalimumab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::df7be6b7f85cae41b087c60d81d8ee23
https://doi.org/10.1136/annrheumdis-2016-eular.1393

FRI0548 Responsiveness of A New MRI Scoring Method Based on The Canada-Denmark Definitions of Lesions in The Spine and The SPARCC MRI Spine Inflammation Index in Patients with Axial Spondyloarthritis: Table 1

Autor: Susanne Juhl Pedersen, Mette Østergaard, Bente Jensen, Inge Juul Sørensen, Lone Balding, Grith Eng, Karsten Asmussen, Ole Rintek Madsen, Simon Krabbe, Jakob M Møller

Publikováno v: Annals of the Rheumatic Diseases. 75:638.3-639

Background The Spondyloarthritis Research Consortium of Canada (SPARCC) Spine Inflammation Index is a well-established MRI scoring system for vertebral body inflammation.(1) It does not take the exact anatomical location of lesions into account. The

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::85223a31221d6bb2b55e4f98387d6650
https://doi.org/10.1136/annrheumdis-2016-eular.1386